Yoshiaki Tomiyama

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0.

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0.

Journal: American journal of hematology

Published: December 18, 2025

Complement activation profile in adult primary immune thrombocytopenia.

Complement activation profile in adult primary immune thrombocytopenia.

Journal: Blood

Published: December 05, 2025

Correction: A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

Correction: A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

Journal: International journal of hematology

Published: August 19, 2025

A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

Journal: International journal of hematology

Published: January 06, 2025

Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.

Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.

Journal: Annals of hematology

Published: November 12, 2024

Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.

Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.

Journal: International journal of hematology

Published: October 30, 2024

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.

Journal: Blood advances

Published: September 18, 2024

A nonactivating ITGB3 mutation in the β3 cytoplasmic region causes macrothrombocytopenia with an impaired αIIbβ3/RhoA pathway.

A nonactivating ITGB3 mutation in the β3 cytoplasmic region causes macrothrombocytopenia with an impaired αIIbβ3/RhoA pathway.

Journal: Blood vessels, thrombosis & hemostasis

Published: May 20, 2024

Haematopoietic regeneration by HLA-A*0206-deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment.

Haematopoietic regeneration by HLA-A*0206-deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment.

Journal: British journal of haematology

Published: March 17, 2024

Comparison of platelet transfusion effectiveness between Helicobacter pylori-positive and -negative immune thrombocytopenia.

Comparison of platelet transfusion effectiveness between Helicobacter pylori-positive and -negative immune thrombocytopenia.

Journal: British journal of haematology

Published: January 06, 2024

Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study.

Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study.

Journal: American journal of hematology

Published: August 16, 2023

Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition.

Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition.

Journal: International journal of hematology

Published: August 04, 2023

Showing 1-12 of 78

Last Updated: 09/26/2026